{
  "title": "How Effective Are Antibody Treatments For COVID-19?",
  "description": "The FDA has issued emergency use authorizations for two monoclonal antibody treatments for COVID-19 – one produced by Eli Lilly and another by Regeneron. As science correspondent <a href=\"https://www.npr.org/people/2100631/richard-harris\">Richard Harris</a> explains, emergency use  authorization doesn't assure that these new drugs are effective, but that their potential benefits are likely to outweigh the risks. So today, we get to the bottom of how this type of treatment works and if they'll really make a difference.<br/><br/>Email the show your questions, coronavirus or otherwise, at <a href=\"https://www.npr.org/sections/health-shots/2020/11/10/933444237/fda-oks-eli-lilly-covid-19-drug-but-supplies-will-be-limited\">shortwave@npr.org</a>.",
  "pubDate": "Mon, 07 Dec 2020 04:00:00 -0500",
  "copyright": "Copyright 2019-2021 NPR - For Personal Use Only",
  "guid": "05de22b0-630b-41e9-8555-29220c98e083",
  "link": "https://www.npr.org/2020/12/04/942919330/how-effective-are-antibody-treatments-for-covid-19",
  "itunes:title": "How Effective Are Antibody Treatments For COVID-19?",
  "itunes:author": "NPR",
  "itunes:summary": "Science correspondent Richard Harris explains how monoclonal antibody treatments for COVID-19 work and how effective they're shaping up to be.",
  "itunes:subtitle": "Science correspondent Richard Harris explains how monoclonal antibody treatments for COVID-19 work and how effective they're shaping up to be.",
  "itunes:image": "",
  "itunes:duration": 726,
  "itunes:explicit": "no",
  "itunes:episodeType": "full",
  "content:encoded": "The FDA has issued emergency use authorizations for two monoclonal antibody treatments for COVID-19 – one produced by Eli Lilly and another by Regeneron. As science correspondent <a href=\"https://www.npr.org/people/2100631/richard-harris\">Richard Harris</a> explains, emergency use  authorization doesn't assure that these new drugs are effective, but that their potential benefits are likely to outweigh the risks. So today, we get to the bottom of how this type of treatment works and if they'll really make a difference.<br/><br/>Email the show your questions, coronavirus or otherwise, at <a href=\"https://www.npr.org/sections/health-shots/2020/11/10/933444237/fda-oks-eli-lilly-covid-19-drug-but-supplies-will-be-limited\">shortwave@npr.org</a>.",
  "enclosure": ""
}